Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Female Sexual Dysfunction

Clayton, Anita H., Valladares Juarez, Elia Margarita · 2019 · Medical Clinics of North America

Abstract

Female sexual dysfunction can drastically diminish quality of life for many women. It is estimated that in the United States 40% of women have sexual complaints. These conditions are frequently underdiagnosed and undertreated. Terminology and classification systems of female sexual dysfunction can be confusing and complicated, which hampers the process of clinical diagnosis, making accurate diagnosis difficult. There are few treatment options available for female sexual dysfunctions, however, some interventions may be of benefit and are described. Additional treatments are in development. The development of clear clinical categories and diagnostic guidelines for female sexual dysfunction are of utmost importance and can be of great benefit for clinical and public health uses and disease-related research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mcna.2019.02.008

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 74

  1. Wright, 2015, Female sexual dysfunction, Med Clin North Am, 99, 607, 10.1016/j.mcna.2015.01.011 · DOI
  2. Sungur, 2014, A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges, J Sex Med, 11, 364
  3. Sand, 2007, Women’s endorsement of models of female sexual response: the nurses’ sexuality study, J Sex Med, 4, 708
  4. Giles, 2009, Conceptualizing women’s sexual function: linear vs. circular models of sexual response, J Sex Med, 6, 2761
  5. Giraldi, 2015, Endorsement of models describing response of men and women with a sexual partner: an online survey in a population sample of Danish adults ages 20-65 years, J Sex Med, 12, 116
  6. Sarin, 2013, Disentangling desire and arousal: a classificatory conundrum, Arch Sex Behav, 42, 1079, 10.1007/s10508-013-0100-6 · DOI
  7. DeRogatis, 2011, Should sexual desire and arousal disorders in women be merged?, Arch Sex Behav, 40, 217, 10.1007/s10508-010-9677-1 · DOI
  8. Segraves, 2007, Proposal for changes in diagnostic criteria for sexual dysfunctions, J Sex Med, 4, 567
  9. Basson, 2001, Female sexual response: the role of drugs in the management of sexual dysfunction, Obstet Gynecol, 98, 350
  10. Hayes, 2006, What can prevalence studies tell us about female sexual difficulty and dysfunction?, J Sex Med, 3, 589
  11. Khajehei, 2015, An update on sexual function and dysfunction in women, Arch Womens Ment Health, 18, 423, 10.1007/s00737-015-0535-y · DOI
  12. Kingsberg, 2015, The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder, CNS Drugs, 29, 915, 10.1007/s40263-015-0288-1 · DOI
  13. Schultz, 1999, Magnetic resonance imaging of male and female genitals during coitus and female sexual arousal, BMJ, 319, 1596, 10.1136/bmj.319.7225.1596 · DOI
  14. Nastri, 2013, Hormone therapy for sexual function in perimenopausal and postmenopausal women, Cochrane Database Syst Rev
  15. Shifren, 2006, Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study, Menopause, 13, 770, 10.1097/01.gme.0000227400.60816.52 · DOI · Paper page
  16. North American Menopause Society, 2005, The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society, Menopause, 12, 496
  17. Davis, 2016, Androgens and female sexual function and dysfunction- findings from the fourth International Consultation of Sexual Medicine, J Sex Med, 13, 168
  18. Fooladi, 2012, An update on the pharmacological management of female sexual dysfunction, Expert Opin Pharmacother, 13, 2131, 10.1517/14656566.2012.725046 · DOI
  19. Goldstat, 2003, Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women, Menopause, 10, 390, 10.1097/01.GME.0000060256.03945.20 · DOI · Paper page
  20. Cayan, 2008, Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women, J Sex Med, 5, 132
  21. Wu, 2001, Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy, Climacteric, 4, 314, 10.1080/cmt.4.4.314.319 · DOI
  22. Nijland, 2008, Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial, J Sex Med, 5, 646
  23. Constantine, 2015, Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial, Climacteric, 18, 226, 10.3109/13697137.2014.954996 · DOI
  24. Portman, 2013, Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy, Menopause, 20, 623, 10.1097/gme.0b013e318279ba64 · DOI · Paper page
  25. Cui, 2014, Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy, J Sex Med, 11, 487
  26. Vallejos, 2016, Flibanserin: a novel, nonhormonal agent for the treatment of hypoactive sexual desire disorder in premenopausal women, J Pharm Pract
  27. Simon, 2014, Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial, Menopause, 21, 633, 10.1097/GME.0000000000000134 · DOI
  28. Gao, 2015, Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis, J Sex Med, 12, 2095
  29. Berman, 2003, Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study, J Urol, 170, 2333
  30. Basson, 2002, Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder, J Womens Health Gend Based Med, 11, 367, 10.1089/152460902317586001 · DOI · Paper page
  31. Caruso, 2001, Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study, BJOG, 108, 623
  32. Meston, 2008, Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women, Arch Sex Behav, 37, 530, 10.1007/s10508-008-9316-2 · DOI
  33. Ito, 2006, The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status, J Sex Marital Ther, 32, 369, 10.1080/00926230600834901 · DOI
  34. Wilson, 2001, Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device, J Gend Specif Med, 4, 54
  35. Seagraves, 2004, Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women, J Clin Psychopharmacol, 24, 339, 10.1097/01.jcp.0000125686.20338.c1 · DOI · Paper page
  36. Kinsberg, 2013, Characterization of orgasmic difficulties by women: focus group evaluation, J Sex Med, 10, 2242
  37. Fisher, 1983, Patterns of female arousal during sleep and waking: vaginal thermoconductance studies, Arch Sex Behav, 12, 97, 10.1007/BF01541556 · doi:10.1007/bf01541556
  38. Wells, 1983, Nocturnal orgasms: females’ perception of a “normal” sexual experience, J Sex Res, 22, 412
  39. Komisaruk, 2005, Functional MRI of the brain during orgasm in women, Annu Rev Sex Res, 16, 62
  40. Dunn, 2005, Genetic influences on variation in female orgasmic function: a twin study, Biol Lett, 1, 260, 10.1098/rsbl.2005.0308 · DOI
  41. Perlis, 2009, Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients, Neuropsychopharmacology, 34, 1819, 10.1038/npp.2009.4 · DOI
  42. Braun, 2001, Socio-cultural representations of the vagina, J Reprod Infant Psychol, 18, 17, 10.1080/02646830020032374 · DOI · Paper page
  43. Schick, 2010, Genital appearance dissatisfaction: implications for women’s genital image self-consciousness, sexual esteem, sexual satisfaction, and sexual risk, Psychol Women Q, 34, 394, 10.1111/j.1471-6402.2010.01584.x · DOI · Paper page
  44. Birnbaum, 2003, The meaning of heterosexual intercourse among women with female orgasmic disorder, Arch Sex Behav, 32, 61, 10.1023/A:1021845513448 · DOI
  45. Burri, 2009, Emotional intelligence and its association with orgasmic frequency in women, J Sex Med, 6, 1930
  46. Rowland, 2016, Understanding orgasmic difficulty in women, J Sex Med, 13, 1246
  47. Redelman, 2006, A general look at female orgasm and anorgasmia, Sex Health, 3, 143, 10.1071/SH06005 · DOI
  48. Kamenov, 2007, Effect of tibolone on sexual function in late postmenopausal women, Folia Med (Plovdiv), 49, 41
  49. Jacques, 2010, Women’s sexual pain disorders, J Sex Med, 7, 616
  50. Simonelli, 2014, Female sexual pain disorders: dyspareunia and vaginismus, Curr Opin Psychiatry, 27, 406, 10.1097/YCO.0000000000000098 · DOI
  51. Cherner, 2013, A psychophysiological investigation of sexual arousal in women with lifelong vaginismus, J Sex Med, 42, 1605
  52. Melzack, 1975, The McGill Pain Questionnaire: major properties and scoring methods, Pain, 1, 277, 10.1016/0304-3959(75)90044-5 · DOI · Paper page
  53. Sullivan, 1995, The pain catastrophizing scale: development and validation, Psychol Assess, 7, 524, 10.1037/1040-3590.7.4.524 · doi:10.1037/1040-3590.7.4.524 · Paper page
  54. Hummel-Berry, 2007, Reliability and validity of the vulvar functional status questionnaire (VQ), J Womens Health Phys Therap, 31, 1605
  55. Friederich, 1987, Vulvar vestibulitis syndrome, J Reprod Med, 32, 110
  56. 2016, The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer, Obstet Gynecol, 127, e93, 10.1097/AOG.0000000000001351 · DOI · Paper page
  57. Bachmann, 2010, Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study, Menopause, 17, 480, 10.1097/gme.0b013e3181c1ac01 · DOI · Paper page
  58. Leo, 2013, A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain, J Sex Med, 10, 2497
  59. Rosen, 2014, Impact of male partner responses on sexual function in women with vulvodynia and their partners - a dyadic daily experience study, Health Psychol, 33, 823, 10.1037/a0034550 · DOI
  60. Melles, 2014, Automatic and deliberate affective associations with sexual stimuli in women with lifelong vaginismus before and after therapist aided exposure treatment, J Sex Med, 11, 786
  61. Ter Kuile, 2015, Therapist aided exposure for women with lifelong vaginismus: mediators of treatment outcome: a randomized waiting list control trial, J Sex Med, 12, 1807
  62. Melnik, 2012, Interventions for vaginismus, Cochrane Database Syst Rev
  63. Atlantis, 2012, Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis, J Sex Med, 9, 1497
  64. Clayton, 2016, Sexual dysfunction due to psychotropic medications, Psychiatr Clin North Am, 39, 427, 10.1016/j.psc.2016.04.006 · DOI
  65. Clayton, 2006, Major depressive disorder, antidepressants, and sexual dysfunction, J Clin Psychiatry, 67, 33
  66. Taylor, 2013, Strategies for managing sexual dysfunction induced by antidepressant medication, Cochrane Database Syst Rev
  67. Landen, 1999, Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors, J Clin Psychopharmacol, 19, 268, 10.1097/00004714-199906000-00012 · DOI · Paper page
  68. Nunberg, 2008, Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial, JAMA, 300, 395, 10.1001/jama.300.4.395 · DOI · Paper page
  69. Lorenz, 2014, Exercise improves sexual function in women taking antidepressants: results from a randomized crossover trial, Depress Anxiety, 31, 188, 10.1002/da.22208 · DOI
  70. Ozmenler, 2008, Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors, Hum Psychopharmacol, 23, 321, 10.1002/hup.929 · DOI
  71. Clayton, 2007, Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder, J Sex Med, 4, 917, 10.1111/j.1743-6109.2007.00520.x · DOI
  72. Clayton, 2006, Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies, J Clin Psychiatry, 67, 736, 10.4088/JCP.v67n0507 · DOI
  73. Thase, 2006, A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability, J Clin Psychopharmacology, 26, 482, 10.1097/01.jcp.0000239790.83707.ab · DOI
  74. Kennedy, 2006, Sexual function during bupropion or paroxetine treatment of major depressive disorder, Can J Psychiatry, 51, 234, 10.1177/070674370605100405 · DOI

Cited by

See all 158

Metadata

Authors
Clayton, A. H., & Valladares Juarez, E. M.
Venue
Medical Clinics of North America
Publisher
Elsevier BV
Published
2019-07
Volume
103
Issue
4
Pages
681-698
ISSN
0025-7125 (ISSN-L)
OpenAlex
W2943900897
Cited by
158
References
13
FWCI
9.31
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Endoceutics, Inc.
  • Janssen
  • Sage Therapeutics
  • Takeda

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Female Sexual Dysfunction. https://app.cochat.ai/papers/10.1016/j.mcna.2019.02.008
The paper
Clayton, A. H., & Valladares Juarez, E. M. (2019). Female Sexual Dysfunction. Medical Clinics of North America. https://doi.org/10.1016/j.mcna.2019.02.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.